Core Viewpoint - The article discusses the implementation and sales performance of the newly established commercial insurance innovative drug directory, highlighting the concentration of sales in major cities and the challenges faced in expanding access to these drugs across the country [3][7]. Summary by Sections Sales Performance of New Drug Directories - As of January 20, 2026, 99 new drugs from the basic medical insurance directory have been sold in 12,198 designated medical institutions, while 14 drugs from the commercial insurance innovative drug directory have been sold in 223 institutions [3][4]. - Over 70% of the commercial insurance innovative drugs have recorded sales, with Alzheimer's disease treatments showing the highest penetration in the hospital market [4][5]. Specific Drug Sales Insights - The drug Lecanemab, developed by Eisai, has been sold in 158 institutions, while Eli Lilly's Donanemab has been recorded in 46 institutions [4]. - The number of patients with mild cognitive impairment or mild dementia due to Alzheimer's disease in China is projected to reach 17 million by 2024, indicating a broad patient base for these treatments [5]. Challenges in Rare Disease Drug Sales - Rare disease drugs face challenges due to their limited patient populations and the concentration of prescriptions in specialized hospitals, resulting in sparse sales data [5][6]. - For instance, Takeda's drug for short bowel syndrome has only been sold in one designated pharmacy in Shenzhen this year [5]. Market Access and Policy Implications - Five innovative drugs have yet to achieve sales in designated medical institutions, including CAR-T products priced between 990,000 to 1.3 million yuan per injection [6]. - The National Healthcare Security Administration has implemented a "three exclusions" policy to facilitate the entry of high-cost drugs into hospitals, but the transition from "entry" to "sales" remains complex due to various factors [6][7]. Regional Disparities in Sales - Sales of commercial insurance innovative drugs are still concentrated in major provinces like Beijing, Shanghai, Jiangsu, and Guangdong, with retail pharmacies accounting for less than 10% of sales [7][8]. - Some regions, such as Guangdong and Chongqing, have begun to support the prescription flow of commercial insurance innovative drugs, but broader implementation is needed [8].

Core Insights - The sales of commercial insurance innovative drugs remain concentrated in public hospitals in a few provinces such as Beijing and Shanghai, with a low proportion of sales through pharmacies [1][5] - As of January 20, 2023, 99 new basic medical insurance drugs were sold in 12,198 designated medical institutions, while 14 commercial insurance innovative drugs were sold in 223 institutions [1][5] Group 1: Sales Data and Trends - Over 70% of commercial insurance innovative drugs have recorded sales, but the specific sales performance varies among the 14 drugs [2] - Alzheimer's disease treatment drugs have the highest penetration in the hospital market, with drugs like Lecanemab and Donanemab achieving sales in 158 and 46 institutions respectively [2] - Multiple anti-tumor drugs are also penetrating the hospital market, with drugs like Ipilimumab and Lurbinectedin being sold in 35 and over 10 institutions respectively [2] Group 2: Challenges and Market Dynamics - Five innovative drugs have not yet formed sales in designated medical institutions, including CAR-T products priced between 990,000 to 1,300,000 yuan per injection [3] - The lack of sales does not imply that these drugs are not benefiting from the supportive policies for commercial insurance innovative drugs [3] - The transition from "hospital entry" to "sales" involves several factors, including physician prescriptions and patient payments, which may hinder the sales volume of these drugs [3] Group 3: Policy and Implementation - Most provinces have clarified that the entry of commercial insurance innovative drugs into hospitals will follow the guidelines of "nationally negotiated drugs" [4] - There is a push for the inclusion of all 19 drugs in the commercial insurance innovative drug directory into the procurement lists of hospitals, which may improve access for patients [4] - The integration of commercial insurance innovative drugs with the dual-channel policy of medical insurance is essential for enhancing confidence in the allocation of these drugs in hospitals [5]

Core Viewpoint - The article discusses the implementation of the first commercial insurance innovative drug directory in China, highlighting the challenges and opportunities for innovative drugs to enter hospitals and outpatient settings under the new policies [3][4][6]. Group 1: Policy Implementation and Impact - The "three exclusions" policy allows innovative drugs included in the commercial insurance directory to be billed separately for inpatient cases, not affecting the bundled payment limits [3][6]. - As of January 8, at least 28 provinces have issued notifications regarding the execution of the national drug directory and the commercial insurance innovative drug directory [6]. - The sales data from the National Healthcare Security Administration indicates that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most had already stocked these drugs prior to the directory's release [6][7]. Group 2: Challenges in Outpatient Use - The outpatient use of commercial insurance innovative drugs remains largely unregulated, with no clear incentives established for outpatient prescriptions [4][10]. - The article notes that while inpatient use may be supported by the "three exclusions" policy, outpatient scenarios face significant barriers, including a lack of payment guarantees from commercial insurance products [10][11]. - The need for clearer guidelines and incentives for outpatient use is emphasized, as many innovative drugs, particularly for cancer and Alzheimer's treatment, are typically administered in outpatient settings [10][11]. Group 3: Market Dynamics and Future Outlook - The article suggests that the success of commercial insurance innovative drugs in hospitals will depend on balancing interests among stakeholders and creating differentiated plans based on local healthcare financing conditions [11][12]. - There is a call for establishing specific standards for exceptional case applications to ensure that patients using commercial insurance innovative drugs are not competing for limited resources with those using nationally negotiated drugs [12][13]. - The potential for hospitals to receive more definitive incentives through "exceptional payments" is highlighted, as this could significantly impact the market volume of commercial insurance innovative drugs [13][14]. Group 4: Retail Pharmacy Integration - The National Healthcare Security Administration has proposed supporting retail pharmacies in stocking drugs from the commercial insurance innovative drug directory, which could enhance access to these medications [15][16]. - However, concerns remain regarding how pricing negotiations and reimbursement rules will be implemented, which could affect the willingness of commercial insurance companies to include these drugs in their coverage [15][16]. - The article stresses the importance of aligning the commercial insurance innovative drug directory with existing healthcare policies to build confidence among healthcare providers in prescribing these medications [16].

Core Viewpoint - The implementation of the first version of the commercial insurance innovative drug directory has begun, with significant implications for the use of innovative drugs in hospitals and outpatient settings, particularly under the "three exclusions" policy [1][3][7]. Group 1: Policy Implementation and Impact - The "three exclusions" policy allows innovative drugs included in the commercial insurance directory to be reimbursed separately from the bundled payment for hospital cases, which is seen as a major benefit for the inclusion of these drugs in hospitals [1][3]. - As of January 8, at least 28 provinces have issued notifications to implement the 2025 version of the national drug directory and the commercial insurance innovative drug directory, indicating a broad acceptance of these policies [3][4]. - The sales data from the National Medical Insurance Administration shows that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most of these were completed before the directory was published [3][4]. Group 2: Challenges in Drug Utilization - There is uncertainty regarding the allocation of special case approvals for commercial insurance innovative drugs, as these approvals are limited to a small percentage of total cases, which may restrict access for patients [8][9]. - The outpatient use of commercial insurance innovative drugs remains largely unregulated, with no existing incentives or policies to support their prescription in outpatient settings [6][12]. - The lack of clear guidelines for the inclusion of commercial insurance innovative drugs in hospital formularies is hindering their adoption compared to nationally negotiated drugs [4][5]. Group 3: Market Dynamics and Future Directions - The market for commercial insurance innovative drugs is expected to grow, but many stakeholders remain cautious due to unresolved issues regarding prescription and payment processes [2][6]. - There is a call for clearer standards and collaboration among departments to ensure the effective use of commercial insurance innovative drugs without being subject to self-payment rate assessments [8][9]. - The potential for outpatient pharmacies to stock commercial insurance innovative drugs is being explored, with some regions already supporting this initiative, but concerns about the integration of outpatient prescriptions into hospital billing remain [11][12].

Core Insights - The commercial insurance innovative drug directory has been officially implemented since January 1, with the inclusion of drugs like Daratumumab β injection, but outpatient incentives for these drugs remain in a policy vacuum [1][2] - The "three exclusions" policy is seen as a significant but challenging measure to facilitate the entry of commercial insurance innovative drugs into hospitals [1][3] - There is a lack of clarity regarding the implementation details for the entry of commercial insurance innovative drugs into hospitals, which limits the ability of medical institutions to stock a wider variety of these drugs [4][5] Group 1 - The first version of the commercial insurance innovative drug directory was launched on January 1, and it includes specific drugs that can be reimbursed separately from the bundled payment system [1] - As of January 8, at least 28 provinces have mandated local medical institutions to hold pharmacy meetings by the end of February to discuss the integration of commercial insurance innovative drugs [2] - The "three exclusions" policy aims to allow innovative drugs to be used in hospitals without affecting the bundled payment system, but its practical implementation remains uncertain [3][7] Group 2 - The entry of commercial insurance innovative drugs into hospitals can either be through inclusion in special drug directories or by facilitating their hospital entry pathways [3] - Recent data shows that from January 1 to 6, over 15 medical institutions recorded sales of commercial insurance innovative drugs, although most of these were pre-configured before the directory's release [3][4] - The sales of commercial insurance innovative drugs are highly concentrated in a few products, particularly those used for Alzheimer's treatment [3] Group 3 - There are currently no specific assessment indicators for the hospital configuration of commercial insurance innovative drugs, unlike the established metrics for national negotiated drugs [4] - Some provinces have clarified that the use of national negotiated drugs will not be included in certain performance assessment metrics for public medical institutions, but it is unclear if this applies to commercial insurance innovative drugs [5] - The transition from hospital entry to patient medication involves prescription and payment processes, which currently face significant bottlenecks, especially in outpatient settings [6] Group 4 - The "three exclusions" policy is expected to be crucial for expanding the hospital sales of commercial insurance innovative drugs, but balancing interests among stakeholders is necessary for effective implementation [7] - A common approach to support the use of innovative drugs in hospitals is to open a "special case negotiation" green channel, but the limited application quota raises concerns about accessibility for commercial insurance innovative drugs [8] - The implementation of "exclusion payment" mechanisms is seen as a more definitive incentive for hospitals to use innovative drugs, but current policies primarily favor national negotiated drugs [9] Group 5 - The commercial insurance innovative drug directory's initial week saw sales primarily occurring in medical institutions, but the market potential remains limited due to the nature of the drugs included [11] - There is a push for retail pharmacies to stock commercial insurance innovative drugs, but concerns about prescription practices and reimbursement processes persist [12] - Future efforts should focus on aligning the commercial insurance innovative drug directory with the national insurance system to enhance confidence in the use of these drugs in hospitals [12]

Core Viewpoint - The acquisition of Green Valley Pharmaceutical by Fosun Pharma marks a significant strategic move into the Alzheimer's disease treatment sector, amidst ongoing controversies and challenges surrounding the drug GV-971 (Guanluotena) [1][2][3] Group 1: Acquisition Details - Fosun Pharma announced an investment of approximately RMB 1.412 billion to acquire a controlling stake in Green Valley Pharmaceutical, which will now become a subsidiary [1][3] - The transaction involves three parts: acquiring existing capital, subscribing to new capital, and addressing stock incentive plans [3] - Post-acquisition, Fosun Pharma will hold 53% of Green Valley's shares, with plans to increase this to 51% through further transfers [3] Group 2: Market Context and Challenges - The Alzheimer's drug market is characterized by high failure rates, with over 99.6% of drug development efforts failing globally [6] - GV-971 has faced significant scrutiny regarding its efficacy and clinical trial design, leading to questions about its market viability [5][6] - The drug's conditional approval requires completion of post-marketing confirmatory clinical trials to maintain its market status [5][8] Group 3: Strategic Implications - Fosun Pharma's entry into the Alzheimer's treatment space is seen as a strategic response to the growing demand for effective therapies in light of China's aging population [7][8] - The acquisition allows Fosun to leverage Green Valley's existing research while avoiding lengthy development timelines associated with new drug discovery [7] - Analysts suggest that the Alzheimer's treatment market is still in its early stages, providing an opportunity for Fosun to establish a competitive advantage [7]

Core Viewpoint - Fosun Pharma is acquiring a controlling stake in Green Valley Pharmaceutical for approximately RMB 1.412 billion, aiming to integrate its Alzheimer's drug, GV-971, into its innovative drug pipeline, despite the drug facing operational challenges and controversies since its launch in 2019 [1][2][3]. Company Summary - Fosun Pharma's acquisition will result in Green Valley becoming a subsidiary, with Fosun holding 53% of its shares post-transaction [5][6]. - The investment will be allocated to clinical research and daily operations of Green Valley, which has been under financial pressure and facing supply issues for GV-971 [1][5]. - The acquisition is seen as a strategic move for Fosun to enter the cognitive disorder treatment market and enhance its position in the neurodegenerative disease sector [4][10]. Industry Summary - The Alzheimer's drug market is experiencing significant activity, with recent approvals of two new targeted therapies, highlighting the competitive landscape [3][9]. - There is a substantial unmet clinical need for effective Alzheimer's treatments, as current options are limited and the disease poses a major public health challenge [5][9]. - The global pharmaceutical industry has invested over $600 billion in Alzheimer's research, with a high failure rate in drug development, indicating the complexities involved in this field [9][11]. - The Chinese government is prioritizing Alzheimer's disease management, with plans to enhance screening and intervention strategies by 2030, which may increase market opportunities [10].

（原标题：年费超10万的老年痴呆症新药，首次进商保） 无论是卫材公司的仑卡奈单抗还是礼来的多奈单抗，患者一年的治疗费用均需超过10万元。高昂的治疗 费用一度让不少阿尔茨海默病（AD）患者家庭在希望与绝望间徘徊，直到首版商保创新药目录为这种 困境带来了转机。 日前，在2025创新药高质量发展大会上，我国首版《商业健康保险创新药品目录》正式发布。两款近年 来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选。而被纳 入商保目录的两款AD药物，都代表了当前阿尔茨海默病治疗领域的最高水平。 AD，作为老龄化社会中的"沉默杀手"，国内患者数量已超1000万。然而，过去由于药物疗效有限且价 格高昂，其临床使用率一直极低。眼下，商保目录意味着，政策在破局。在商保目录推动下， 全球阿 尔茨海默病治疗市场正在经历一场深刻变革。 ...

Core Points - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) along with the first Commercial Health Insurance Innovative Drug Catalog (2025), focusing on high-innovation and clinically valuable drugs [1] - A total of 24 drugs participated in the price negotiation, with 19 successfully included, achieving a success rate of approximately 79% [1] - The included innovative drugs feature 5 CAR-T cell therapies, 6 rare disease drugs, and the only immune oncology drug in the commercial health insurance catalog [1] Group 1: CAR-T Cell Therapies - Five CAR-T cell therapies have been included in the commercial health insurance innovative drug catalog, which had previously attempted to enter the national insurance catalog four times without success [2][3] - The therapies included are from various companies, with the first approved CAR-T therapy being the Axicabtagene Ciloleucel injection from Fosun Kite [3] - Despite high treatment costs, the inclusion in the commercial catalog is expected to improve patient access and reduce financial burdens [3] Group 2: Oncology Drugs - The commercial health insurance innovative drug catalog includes a significant number of oncology drugs, with 14 drugs in total, accounting for nearly 74% of the catalog [5] - Notably, the CTLA-4 inhibitor Ipilimumab injection, the only immune oncology drug included, is expected to enhance treatment accessibility for liver cancer patients [6] Group 3: Rare Disease Drugs - The catalog also includes 6 innovative drugs for rare diseases, such as the drugs for neuroblastoma and phenylketonuria [8][10] - These drugs are aimed at addressing urgent patient needs and are part of a broader strategy to enhance treatment options for rare diseases [8] Group 4: Policy Implications - The establishment of the commercial health insurance innovative drug catalog is a significant step towards improving the multi-tiered medical insurance system in China [9] - The government encourages commercial health insurance providers to incorporate these drugs into their coverage, promoting a more comprehensive healthcare solution for patients [9]

Core Viewpoint - The new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory will be implemented nationwide starting January 1, 2026, providing a dual-track system for basic and innovative drug coverage [1][2]. Group 1: National Medical Insurance Directory - A total of 114 new drugs have been added to the National Medical Insurance Directory, with 111 being new products launched within the last five years, representing 97.3% of the new entries [2]. - Among the new additions, 50 are classified as Class 1 innovative drugs, with an overall success rate of 88%, an increase from 76% in 2024 [2]. - The total number of drugs in the directory has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. Group 2: Company Announcements - Several listed companies, including Heng Rui Medicine and Fuxing Medicine, announced new drug entries or renewals in the National Medical Insurance Directory [3]. - Heng Rui Medicine reported that 20 products/indications were included in the new directory, with a projected sales revenue of approximately 8.66 billion yuan in 2024 and about 7.55 billion yuan in the first three quarters of 2025 [4]. - Hai Si Ke's two Class 1 innovative drugs were also included, with applications in sedation and pain management [6]. Group 3: Commercial Health Insurance Innovative Drug Directory - The first Commercial Health Insurance Innovative Drug Directory includes 19 new drugs from 18 innovative pharmaceutical companies, with 9 being Class 1 innovative drugs [11]. - Notably, 5 CAR-T products were included, representing over half of the CAR-T products available in China, addressing previous challenges in pricing negotiations [11][12]. - The directory also includes treatments for rare diseases and high-profile conditions such as Alzheimer's disease, enhancing the coverage provided by basic medical insurance [11][13].